{"id":"W2094417916","doi":"10.1007/s00280-010-1379-9","title":"Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy","year":2010,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary; McGill University; Dr. H. Bliss Murphy Cancer Centre; Saskatchewan Cancer Agency; Aptose Biosciences (Canada); Alberta Cancer Foundation","funders":"","keywords":"Medicine; Nimotuzumab; Chills; Rash; Toxicity; Internal medicine; Lung cancer; Regimen; Oncology; Gastroenterology; Radiation therapy; Phases of clinical research; Surgery; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001305323,0.001808047,0.002180139,0.0004127521,0.001192164,0.00111461,0.001706154,0.001351076,0.003581967],"category_scores_gemma":[0.0009566557,0.0007256417,0.001471164,0.0008192885,0.001797146,0.0005878107,0.0005813173,0.002806009,0.0006992116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008837877,"about_ca_system_score_gemma":0.0146334,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.192135,"about_ca_topic_score_gemma":0.3913373,"domain_scores_codex":[0.9994677,0.0001520455,0.00001480092,0.00009390238,0.00006055697,0.0002111184],"domain_scores_gemma":[0.999256,0.00004633951,0.00008804821,0.00003852871,0.00005613727,0.0005150796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8786906,0.04507991,0.009917454,0.000277128,0.0009161676,0.0002030945,0.0003972635,0.00201017,0.01493854,0.0002661632,0.004178547,0.04312502],"study_design_scores_gemma":[0.5554565,0.3919136,0.04205998,0.00003589601,0.0008367492,0.0002580257,0.0002083153,0.001589824,0.002379421,0.0002069006,0.004995805,0.00005895392],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935295,0.0009701899,0.0001893387,0.0006027609,0.0001597847,0.001826457,0.0007588581,0.00004896957,0.001914248],"genre_scores_gemma":[0.9911811,0.001311517,0.001075469,0.0005403261,0.0001521758,0.001070667,0.001741083,0.00001976031,0.00290792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.807865,"threshold_uncertainty_score":0.3820332,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03060500181438004,"score_gpt":0.4110274883242362,"score_spread":0.3804224865098562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}